111![HIV Drug Assistance Program HIV Drug Assistance Program](https://www.pdfsearch.io/img/aabae615b20562f227990334e2d6d526.jpg) | Add to Reading ListSource URL: www.ok.govLanguage: English - Date: 2014-09-15 15:17:10
|
---|
112![Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis Daclatasvir TRIO achieves 98% cure Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis Daclatasvir TRIO achieves 98% cure](https://www.pdfsearch.io/img/1744ee22c511bc053d39efd0961cee8d.jpg) | Add to Reading ListSource URL: www.hepcassoc.orgLanguage: English - Date: 2014-11-10 11:48:36
|
---|
113![NDA[removed]Nebivolol/Valsartan Fixed-Dose Combination Forest Research Institute, Inc. Page 2 of 116
NDA[removed]Nebivolol/Valsartan Fixed-Dose Combination Forest Research Institute, Inc. Page 2 of 116](https://www.pdfsearch.io/img/3a830f52e7bd15c805cc2617de5a689b.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
114![NDA 206,302 (Nebivolol/Valsartan Fixed Dose Combination) NDA 206,302 (Nebivolol/Valsartan Fixed Dose Combination)](https://www.pdfsearch.io/img/d045c8a367978e1c95d07ae6aa6af42a.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
115![World Health Organization 2007 All rights reserved. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means
World Health Organization 2007 All rights reserved. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means](https://www.pdfsearch.io/img/375d49e93acd79ff90efcb7767f89ed6.jpg) | Add to Reading ListSource URL: apps.who.intLanguage: English - Date: 2007-11-29 06:59:40
|
---|
116![Oklahoma HDAP Formulary effective[removed]FY 2014 Oklahoma HIV Drug Assistance Program Drug Formulary Brand Generic Aptivus Oklahoma HDAP Formulary effective[removed]FY 2014 Oklahoma HIV Drug Assistance Program Drug Formulary Brand Generic Aptivus](https://www.pdfsearch.io/img/749d80e8e86204abcef3fdd588d24a3e.jpg) | Add to Reading ListSource URL: www.ok.govLanguage: English - Date: 2014-09-15 15:15:59
|
---|
117![WHO Prequalification Team Medicines (PQT-M) Guidance Document 30 September 2014 WHO Prequalification Team Medicines (PQT-M) Guidance Document 30 September 2014](https://www.pdfsearch.io/img/f1a672dcbe411aa63f97f6fc4d73ec3f.jpg) | Add to Reading ListSource URL: apps.who.intLanguage: English - Date: 2014-09-29 08:36:12
|
---|
118![SOGC CLINICAL PRACTICE GUIDELINE No. 310, August 2014 Guidelines for the Care of Pregnant Women Living With HIV and Interventions to Reduce Perinatal Transmission SOGC CLINICAL PRACTICE GUIDELINE No. 310, August 2014 Guidelines for the Care of Pregnant Women Living With HIV and Interventions to Reduce Perinatal Transmission](https://www.pdfsearch.io/img/f60f51315b46caf878ebb88d84aa2d29.jpg) | Add to Reading ListSource URL: sogc.orgLanguage: English - Date: 2014-09-25 08:34:19
|
---|
119![HIGHLIGHTS OF PRESCRIBING INFORMATION • New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess estimated creatinine HIGHLIGHTS OF PRESCRIBING INFORMATION • New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess estimated creatinine](https://www.pdfsearch.io/img/3ffb4763e39baaa169f589e0ceefafcf.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2013-11-05 15:14:28
|
---|
120![CrCl is below 60 mL/min. If a decrease in CrCl is observed in uninfected individuals while using TRUVADA for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use[removed]HIGHLIGHTS CrCl is below 60 mL/min. If a decrease in CrCl is observed in uninfected individuals while using TRUVADA for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use[removed]HIGHLIGHTS](https://www.pdfsearch.io/img/7a3e9fd8d521106f0076e6a6e90fe9dc.jpg) | Add to Reading ListSource URL: www.gilead.comLanguage: English - Date: 2013-12-17 08:54:34
|
---|